• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)

PRODUCT FILTERS

REGION

370
58
43
41
20

COUNTRY

40
8
5
5
4

PRICE

136
413
509
1,026

PUBLISHED

16
60
287
1,026

PRODUCT TYPE

993
17
11
4
1

Central Nervous System

In 2012 major changes might revolutionize the treatment of multiple sclerosis, as Gilenya, the first novel drug in five years, will be joined by three new products: BG-12, Aubagio, and Lemtrada. Recent exciting developments in drug discovery might also enhance the hopes of those fighting against Alzheimer.

Great commercial and scientific opportunities are to be found in similar battles against a range of diseases and neurodegenerative disorders, e.g. Parkinson’s disease, schizophrenia, migraine, insomnia, epilepsy, etc.

A wide selection of industry reports, scientific journals and academic textbooks in this section allow readers to explore every conceivable facet of this industry, such as market trends, industry forecasts, new drugs in development, the latest research & development, patent applications, and licensing strategies.

Key players featured in our publications include Biogen Idec, Sanofi, Genzyme, and many more. Show Less
Read more

PRODUCT TITLE

Partial Seizure - Pipeline Review, H2 2013

Partial Seizure - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Partial Seizure - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report...

October 2013
FROM

Traumatic Brain Injury - Pipeline Review, H2 2013

Traumatic Brain Injury - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Traumatic Brain Injury - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline....

October 2013
FROM

Psychiatric Disorders - Pipeline Review, H2 2013

Psychiatric Disorders - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Psychiatric Disorders - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline....

October 2013
FROM

Memory Impairment - Pipeline Review, H2 2013

Memory Impairment - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Memory Impairment - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report...

October 2013
FROM

Neuropathy - Pipeline Review, H2 2013

Neuropathy - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Neuropathy - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

October 2013
FROM

Chronic Pain - Pipeline Review, H2 2013

Chronic Pain - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Chronic Pain - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

October 2013
FROM

Anesthetic Effect - Pipeline Review, H2 2013

Anesthetic Effect - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Anesthetic Effect - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report...

October 2013
FROM

Sedation - Pipeline Review, H2 2013

Sedation - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Sedation - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information...

October 2013
FROM
Frontiers in Clinical Drug Research - Central Nervous System: Volume 1 Frontiers in Clinical Drug Research - Central Nervous System: Volume 1 - Product Thumbnail Image

Frontiers in Clinical Drug Research - Central Nervous System: Volume 1

Frontiers in Clinical Drug Research – Central Nervous System presents the latest researches and clinical studies on the central nervous system (CNS) It covers a range of topics such as the development...

October 2013

Frontiers in Clinical Drug Research - CNS and Neurological Disorders: Volume 2

Frontiers in Clinical Drug Research - CNS and Neurological Disorders is an ebook series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for...

October 2013

EpiCast Report: Autism Spectrum Disorders - Epidemiology Forecast to 2022

EpiCast Report: Autism Spectrum Disorders - Epidemiology Forecast to 2022 Summary Autism Spectrum Disorders (ASD) is a group of incurable, developmental disabilities which affect the brain and are...

October 2013
FROM

EpiCast Report: Postherpetic Neuralgia - Epidemiology Forecast to 2022

EpiCast Report: Postherpetic Neuralgia - Epidemiology Forecast to 2022 Summary Postherpetic Neuralgia (PHN) is one of the most common complications of herpes zoster infection in elderly persons ages...

October 2013
FROM

Dementia Global Clinical Trials Review, H2, 2013

“Dementia Global Clinical Trials Review, H2, 2013" provides data on the Dementia clinical trial scenario This report provides elemental information and data relating to the clinical trials on Dementia...

October 2013
FROM

Migraine Global Clinical Trials Review, H2, 2013

Migraine Global Clinical Trials Review, H2, 2013 Summary Our clinical trial report, “Migraine Global Clinical Trials Review, H2, 2013" provides data on the Migraine clinical trial scenario. This report...

October 2013
FROM

Epilepsy Global Clinical Trials Review, H2, 2013

Epilepsy Global Clinical Trials Review, H2, 2013 Summary Our clinical trial report, “Epilepsy Global Clinical Trials Review, H2, 2013" provides data on the Epilepsy clinical trial scenario. This report...

October 2013
FROM
Disease and Therapy Review: Migraine Disease and Therapy Review: Migraine - Product Thumbnail Image

Disease and Therapy Review: Migraine

The Migraine Disease and Therapy Review provides an overview of the disease and related conditions, with prevalence numbers and percentages for major countries worldwide, information on diagnosis, and...

October 2013
FROM
Disease and Therapy Review: Major Depressive Disorder Disease and Therapy Review: Major Depressive Disorder - Product Thumbnail Image

Disease and Therapy Review: Major Depressive Disorder

The Major Depressive Disorder Disease and Therapy Review provides an overview of the disease and related conditions, with incidence and prevalence numbers and percentages for major countries worldwide,...

October 2013
FROM

Razadyne/Reminyl (Alzheimer's Disease) - Forecast and Market Analysis to 2022

Razadyne/Reminyl (Alzheimer’s Disease) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Razadyne/Reminyl (Alzheimer’s Disease) -...

September 2013
FROM

Exelon (Alzheimer's Disease) - Forecast and Market Analysis to 2022

Exelon (Alzheimer’s Disease) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Exelon (Alzheimer’s Disease) - Forecast and Market...

September 2013
FROM

Aricept (Alzheimer's Disease) - Forecast and Market Analysis to 2022

Aricept (Alzheimer’s Disease) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Aricept (Alzheimer’s Disease) - Forecast and Market...

September 2013
FROM
Loading Indicator

Our Clients

Our clients' logos